致：香港交易及結算所有限公司 公司名稱: 遠大醫藥集團有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00512 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證 ...

2025 年干眼症治疗药物 品牌推荐 市场规模·····十大品牌·排行榜 | 一、市场背景 2 | | --- | | 1.1 摘要 2 | | 1.2 干眼症定义 2 | | 1.3 市场演变 2 | | 二、市场现状 3 | | 2.1 市场规模 3 | | 2.2 市场供需 3 | | 三、市场竞争 4 | | 3.1 市场评估维度 4 | | 3.2 市场竞争格局 4 | | 3.3 十大品牌推荐 4 | | 四、发展趋势 6 | | 4.1 市场规模持续增长 6 | | 4.2 药物创新多元化发展 7 | | 4.3 本土企业崛起与全球化布局 7 | | 4.4 竞争格局与风险应对 7 | 2025 年干眼症治疗药物品牌推荐 一、市场背景 1.1 摘要 随着公众对视觉健康关注度的提升，干眼症已从职场及老年群体的"专属困扰"，演变为 覆盖全年龄段的慢性眼部健康挑战。2024 年中国干眼症患病人数已达 3.6 亿，但治疗率 仅 10%-12%，市场潜力巨大。制剂技术与给药系统革新推动药物从传统人工泪液向多剂 量无防腐剂制剂、新型递药途径升级，以环孢素滴眼液、全氟己基辛烷眼用制剂等为代 表的新机制疗法成为 ...

Core Insights - The article highlights the top short-selling stocks in the market, indicating significant investor sentiment and potential market movements [1][2]. Short Selling Ratios - The highest short-selling ratio is observed in China Resources Beer (80291) at 100.00%, followed by JD Group (89618) at 92.61% and AIA Group (81299) at 82.83% [1][2]. - Other notable companies with high short-selling ratios include New World Development (80016) at 69.99% and Xiaomi Group (81810) at 69.65% [2]. Short Selling Amounts - The top three companies by short-selling amount are Meituan (03690) with 1.899 billion, Xiaomi Group (01810) with 1.248 billion, and Tencent Holdings (00700) with 1.223 billion [1][2]. - Alibaba (09988) follows with a short-selling amount of 1.107 billion, indicating substantial investor activity in these stocks [2]. Deviation Values - The highest deviation values, which reflect the difference between current short-selling ratios and the average over the past 30 days, are led by Yuan Da Pharmaceutical (00512) at 42.04%, Yuexiu Property (00123) at 40.19%, and COFCO Joycome (01610) at 39.65% [1][2]. - Other companies with significant deviation values include Sunac Services (01516) at 39.64% and China Ship Leasing (03877) at 39.39% [2].

如同最初的创新药一般，近两年来，中国创新医疗器械BD也正逐渐起势。 日前，国家药监局宣布多款创新医疗器械获批上市，其中，一次性使用外周血管血栓旋切导管为国内首创，并达 到国际先进水平。与此同时，又有十多款产品公告进入创新医疗器械特别审批程序。公开数据显示，2025年国家 药监局已公告122款产品进入创新医疗器械特别审批程序，较2024年近乎翻倍。 中国创新医疗器械，即将迎来自己的"创新药"时刻？ 01 国内创新医疗器械BD也疯狂 回顾中国创新药的崛起，从2024年开始，中国创新药得到全球关注并被MNC大肆买进成为了一个标志。彼时正是 在美国生物技术生态普遍低迷之际，中国创新药反而逆势而上，成为"卖方市场"的主角。 2025年，这种趋势更是势不可挡。据医药魔方NextPharma数据库显示，2025年中国创新药共完成157起BD出海授 权交易，交易总额为1356.55亿美元，其中首付款70亿美元，这三项关键数据均创下历史新高。 此外，在超高额BD交易中，2025年全球医药License-out交易总额Top10有8项来自中国，另外总交易额超过百亿美 元4起中，中国独占3起。这些高额交易使得中国创新药2025年B ...

Group 1 - The biopharmaceutical industry is crucial for public welfare and is a key driver for high-quality development in the pharmaceutical sector, with a focus on future industries like quantum technology and biomanufacturing as new economic growth points [1] - Chengdu's Wenjiang District has established a comprehensive biopharmaceutical ecosystem that integrates medical research, healthcare services, and pharmaceutical manufacturing, starting its development in 2008 [1] - The district's government has implemented a "three medicine" integration concept to promote cluster development in the biopharmaceutical industry, breaking down silos between medical research, healthcare, and pharmaceuticals [1] Group 2 - Chengdu Baiyu Pharmaceutical Co., Ltd. is a local biopharmaceutical company that has benefited from government initiatives such as specialized financing and subsidies, which have supported its research and development efforts [2] - Sichuan Baili Tianheng Pharmaceutical Co., Ltd., a leader in innovative cancer therapies, has achieved a significant global collaboration worth $8.4 billion with Bristol-Myers Squibb for its pioneering ADC product [2] - Wenjiang District has attracted key industry players through targeted investment strategies, establishing a distinctive and efficient biopharmaceutical industry chain, including a specialized nuclear medicine industrial park [3] Group 3 - The district has over 650 enterprises in the pharmaceutical and health sectors, forming a complete industrial ecosystem that includes drug research, manufacturing, and medical applications, with significant achievements in innovative drug development [3] - Companies in the region have successfully engaged in international drug licensing transactions, totaling over $24 billion, showcasing their strong research capabilities [3] - Wenjiang District is committed to becoming a leading biopharmaceutical hub in Western China, with plans to enhance support policies for the industry [4]

证券研究报告 行业周报 礼来替尔泊肽全线爆发，2025年合计贡献365亿美元 生物医药行业强于大市（维持） 平安证券研究所生物医药团队 分析师： 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 倪亦道投资咨询资格编号:S1060518070001邮箱：NIYIDAO242@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 裴晓鹏投资咨询资格编号:S1060523090002邮箱：PEIXIAOPENG719@PINGAN.COM.CN 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 王钰畅投资咨询资格编号:S1060524090001邮箱：WANGYUCHANG804@PINGAN.COM.CN 曹艳凯投资咨询资格编号:S1060524120001邮箱：CAOYANKAI947@PINGAN.COM.CN 张梦鸽投资咨询资格编号:S1060525070003邮箱：ZHANGMENGGE752@PINGA ...

Group 1 - The meeting was chaired by the Secretary of the Municipal Party Committee, Qie Yingcai, to discuss the development of private enterprises and gather opinions from business representatives [2] - Company leaders from various sectors, including Huaxin Building Materials and Zhenhua Chemical, shared their operational conditions for 2025 and work goals for 2026, focusing on issues like equipment upgrades and talent recruitment [3] - Qie Yingcai expressed gratitude for the contributions of private enterprises to the economic and social development of Huangshi, emphasizing the importance of these businesses in achieving the province's economic goals [5] Group 2 - The city aims to maintain its economic indicators in the top tier of the province by 2025, with a focus on high-quality development and improved administrative efficiency to support private enterprises [5] - Wu Zhiling highlighted the need for greater emphasis on talent development and technological innovation, as well as the integration of resources within the manufacturing industry to enhance competitiveness [7] - The meeting included participation from various city leaders, indicating a collaborative approach to addressing the challenges faced by the manufacturing sector [7]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00512 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 第 ...

Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號: 00512) 補充及澄清公告 關連交易 收購河北遠大九孚生物科技有限公司及 保定加合精細化工有限公司全部股權 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 茲提述本公司於二零二五年十二月三十一日刊發有關股份購買協議項下擬進行交易之關連 交易之公告（「該公告」）。除另有說明外，本補充公告所用詞彙與該公告所界定者具 有相同涵義。 誠如公告所披露，本次交易之代價人民幣 316,000,000 元乃經買方與賣方參考下列因素後， 經公平磋商釐定：(i)目標公司之財務表現、業務增長及前景（包括現有資產、研發進程中 之技術專長及研發項目之未來前景）； (ii) 獨立合資格估值師根據市場法編製之估值報告， 據此，於扣除建議向賣方分派之利潤人民幣 134,000,000元後，目標公司 100%股權於 2025 年 9 月 30 ...

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies. Core Insights - The report highlights significant developments in the overseas pharmaceutical sector, including the collaboration between Insilico Medicine and Heng Tai Biopharma to develop a novel NLRP3 inhibitor for central nervous system diseases [2][6]. - The report notes that MicroPort Robotics expects a revenue growth of approximately 110%-120% year-on-year for 2025, with an adjusted net loss not exceeding 240 million yuan, representing a reduction of over 50% [5][6]. - GSK has reached a final agreement to acquire RAPT Therapeutics for approximately 2.2 billion USD, focusing on a long-acting monoclonal antibody currently in clinical trials [7][8]. Summary by Sections 1. Overseas Pharmaceuticals - Insilico Medicine and Heng Tai Biopharma have entered a partnership to develop ISM8969, a novel oral NLRP3 inhibitor, with both companies holding 50% global rights [2][6]. - The Hong Kong Stock Exchange has approved the full circulation of 182,645,856 H shares for Fuhong Hanlin, representing about 33.61% of the company's total issued shares as of January 19 [2][6]. - The new drug application for TLX591-CDx, a radiopharmaceutical for prostate cancer diagnosis, has been accepted by the NMPA [2][6]. 2. Company Updates - MicroPort Robotics has reported over 180 commercial orders and more than 120 installations globally as of January 21 [5][6]. - Legend Biotech, a joint venture of Genscript Biotech, reported a trade sales net of approximately 555 million USD for the quarter ending December 31, 2025 [5][6]. - GSK's acquisition of RAPT Therapeutics includes a payment of 58.00 USD per share, with an expected upfront investment of 1.9 billion USD after cash adjustments [7][8]. 3. Market Performance - The Hang Seng Healthcare Index fell by 4.35%, underperforming the Hang Seng Index by 3.26 percentage points [4]. - The report indicates a strong performance in the overseas education sector, with GMV for Dongfang Zhenxuan reaching approximately 310 million yuan, a 42.8% increase week-on-week [15][16]. 4. Recommendations - The report suggests focusing on innovative drugs and the ongoing clinical progress of key pipelines from companies such as BeiGene, Innovent Biologics, and others [12]. - It also recommends monitoring the performance of educational companies like Dongfang Zhenxuan and China Oriental Education, which are expected to benefit from improved operational strategies and increased enrollment [16].